LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions announced that Dr. Steven O’Day, Chief of Research and Director of the Melanoma Program at The Angeles Clinic and Research Institute in Los Angeles, will present an update on the results of a Phase 2b study of STA-4783 in combination with paclitaxel compared to paclitaxel alone in the treatment of metastatic melanoma at the European Association of Dermato-Oncology (EADO) in Barcelona, Spain, September 6-8, 2007.
